TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05588219
Drug: DDP synchronous with radiotherapy
Normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DDP 40mg/m2/W, synchronous with radiotherapy, complete at least 4 cycles.
Study: NCT05673369
Drug: CKD-387
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Tablet
Study: NCT05673369
Drug: D484
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 Tablet
Study: NCT05698524
Drug: PCI 24781
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take the PCI-24781/Abexinostat on days 1-4, 8-11, 15-18, and 22-25 of each 28-day cycle.
Study: NCT05698524
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive temozolomide at a dose of 50 mg/mg2, taken by mouth once daily.
Study: NCT04918810
Drug: Docetaxel intermittent
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After 3 or 4 cycles of docetaxel chemotherapy (75mg/m\^2 every 21 days or 50mg/m\^2 every 14 days) in combination with an undetectable mGSTP1 level, patients will stop docetaxel treatment. Plasma mGSTP1 is measured every 21 days or 28 days (depending on Docetaxel regimen) and docetaxel treatment will be recommenced if it mGSTP1 becomes detectable again.
Study: NCT04957914
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT00864409
Drug: ropivacaine 0,2%
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local wound infiltrtation with 170 mL ropivacaine 2 mg/mL
Study: NCT05180825
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mekinist© (Trametinib) taken orally each day with a 18-course schedule of 4 weeks each.
Study: NCT05180825
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each
Study: NCT04653246
Drug: Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Via IV at predetermined dosage and predetermined days during each cycle
Study: NCT04653246
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral, predetermined dosage and predetermined days during each cycle
Study: NCT04653246
Drug: Bortezomib Injection
Normalized name: bortezomib Injection
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SQ Oral, predetermined dosage and predetermined days during each cycle
Study: NCT04653246
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV or Oral predetermined dosage and predetermined days during each cycle
Study: NCT05688384
Drug: Propofol + Alfentanil
DrugBank: Alfentanil (DB00802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In addition to LA, patients in the study group are able to self-administer a combination of propofol and alfentanil using a patient-controlled sedation pump. The pump enables the patient via a hand-held button to trigger the release of a single bolus of 0.5ml containing 4.5mg propofol and 25µg alfentanil under an 10second period. This results in a maximal possible amount of 6 bolus doses per minute.
Study: NCT05532423
Drug: Beetroot Juice - Active
Normalized name: tamarind juice
DrugBank: Beet (DB10640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This juice will be the active juice, meaning it has the high nitrate content that is of interest. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
Study: NCT05805683
Drug: Calcitonin
Normalized name: Calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in this group will receive 100 IU (1 ml) of calcitonin subcutaneously per day for 2 weeks starting within 48 hours after injury.
Study: NCT05532423
Drug: beetroot juice - Placebo
DrugBank: Beet (DB10640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This drink will be the placebo drink, which means all of the nitrate has been extracted, however it tastes and smells the same as the active drink. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
Study: NCT06297941
Drug: REM-422
Normalized name: REM-422
DrugBank: REM-422 (DB19304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~REM-422 will be administered orally once daily
Study: NCT04840901
Drug: Lebrikizumab
Normalized name: Lebrikizumab
DrugBank: Lebrikizumab (DB11914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05957913
Drug: Truvada (tenofovir/emtricitabine)
Normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doses and route of administration of the study drug will be kept the same as for the FDA-approved indication of HIV-1 prevention in healthy individuals. The study drug is not FDA-approved for the treatment of multiple sclerosis.
Study: NCT04269213
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04898894
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given orally (PO)
Study: NCT04898894
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given Orally (PO)
Study: NCT04898894
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given in to the vein (IV) or intrathecal (IT)
Study: NCT04898894
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given in to the vein (IV) - Because of the ongoing nationwide shortage of fludarabine, this agent may be omitted during the dose expansion phase of the trial.
Study: NCT04701658
Drug: Bamlanivimab
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously.
Study: NCT06003179
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine given as part of standard treatment
Study: NCT05683496
Drug: lonigutamab
Normalized name: Lonigutamab
DrugBank: Lonigutamab (DB18940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT05244642
Drug: Penpulimab
Normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A humanized monoclonal immunoglobulin.
Study: NCT00005002
Drug: Lamivudine/Zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005002
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05851976
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine 60mg daily for 14 days
Study: NCT05173142
Drug: gemcitabine and cisplatin
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine and Cisplatin administered intravenously.
Study: NCT05173142
Drug: toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab administered intravenously.
Study: NCT05173142
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel administered intravenously.
Study: NCT04546126
Drug: Dexamethasone (Group 2)
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will take 1 mg dexamethasone 2x a day for 3 days to suppress cortisol production.
Study: NCT04546126
Drug: Cosyntropin (Group 3)
Normalized name: Cosyntropin
DrugBank: Tetracosactide (DB01284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
Study: NCT06471231
Drug: vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min in the absence of adequate MAP (Mean arterial pressure \>65 mmhg), vasopressin infusion will be associated with the standard dosage of 0.3UI/min.
Study: NCT06471231
Drug: vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.5 mcg/kg/min
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the infusion of vasopressin at a dosage of 0.3 IU/min will be associated if norepinephrine exceeds the dosage of 0.5 mcg/kg/min in the absence of adequate MAP
Study: NCT05617625
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.8 mg/kg q6h x 12 doses via IV injection on Days -9, -8, and -7 prior to transplant
Study: NCT05617625
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 mg/m\^2/day x 2 days via IV infusion over 30 minutes on Days -6 and -5 prior to transplant
Study: NCT05617625
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/m\^2/days x 5 days via IV infusion over 30 minutes on Days -6, -5, -4, -3, and -2 prior to transplant
Study: NCT04822584
Drug: Baricitinib Oral Product
Normalized name: baricitinib Oral Product
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib 4 mg/day orally for 36 weeks
Study: NCT04461041
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single oral tablet
Study: NCT05168423
Drug: CART-EGFR-IL13Ra2 Cells
Normalized name: prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2
Study: NCT04218825
Drug: chlormethine gel
Normalized name: chlormethine
DrugBank: Mechlorethamine (DB00888)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel to be applied to all skin areas affected by MF-CTCL
Study: NCT05896943
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with ulcerative colitis treated with ustekinumab
Study: NCT06451770
Drug: VERVE-201
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT05027360
Drug: SNP - Sodium Nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The primary objective of our study is to assess the efficacy and safety of SNP as part of the treatment regimen of AHF patients and to identify predictors of efficacy.
Study: NCT04444830
Drug: Sprix
Normalized name: Sprix
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal Ketorolac - used as directed for an appropriate, previously established indication
Study: NCT06652048
Drug: Furmonertinib 160mg QD
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients enrolled into this group will receive furmonertinib 160mg p.o qd.
Study: NCT06652048
Drug: Furmonertinib 240mg QD
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients enrolled into this group will receive furmonertinib 240mg p.o qd.
Study: NCT04825197
Drug: Poractant Alfa Intratracheal Suspension [Curosurf]
Normalized name: poractant alfa Intratracheal Suspension [Curosurf]
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: up to 4 doses (100 mg Kg) of Poractant alfa every 12 hours; each dose preceded by a recruitment manoeuvre in HFOV.
Study: NCT06154278
Drug: Imdusiran (AB-729)
Normalized name: Imdusiran
DrugBank: Imdusiran (DB19014)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg subcutaneously, every 8 weeks, for a total of 4 doses
Study: NCT04711850
Drug: Imlifidase
Normalized name: Imlifidase
DrugBank: Imlifidase (DB15258)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Immunoglobulin G degrading enzyme of Streptococcus pyogenes
Study: NCT04839575
Drug: Latiglutenase
Normalized name: LATIGLUTENASE
DrugBank: Latiglutenase (DB06326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally (daily)
Study: NCT06156761
Drug: Mitoxantrone hydrochloride liposome
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
Study: NCT06156761
Drug: Mitoxantrone hydrochloride liposome
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 4-week treatment cycle.
Study: NCT05551247
Drug: Envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg,sc,d3,Q3W;
Study: NCT05551247
Drug: recombinant human endostatin (endostatin)
Normalized name: Pentostatin
DrugBank: Endostatin (DB06423)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 210mg,civ,d1-3,Q3W
Study: NCT05857930
Drug: OM-85
Normalized name: OM-85
DrugBank: OM85 (DB16533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM-85 capsule (3.5mg) contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.
Study: NCT05399576
Drug: Nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactically combined intracoronary of Nicorandil and verapamil
Study: NCT05399576
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intracoronary of 4ml saline
Study: NCT05267106
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 13.5mg tablet taken every morning (unless otherwise directed) for 2 weeks and then 1 week off.
Study: NCT04998201
Drug: ARO-APOC3
Normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARO-APOC3 Injection
Study: NCT03503890
Drug: rovalpituzumab tesirine
Normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT06406829
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively and 0.05 μg/kg/h for 48 hours after surgery.
Study: NCT05783882
Drug: Prolgolimab
Normalized name: prolgolimab
DrugBank: Prolgolimab (DB16740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Q3W
Study: NCT06430827
Drug: irinotecan hydrochloride liposome injection
Normalized name: irinotecan hydrochloride liposome Injection
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rinotecan hydrochloride liposome injection (70mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
Study: NCT05394831
Drug: JIN-A02
Normalized name: Yu Jin
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, QD
Study: NCT06610279
Drug: TAK-951
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-951 SC injection
Study: NCT05470517
Drug: Ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous, intramuscular, or intra-peritoneal administration.~Ceftriaxone is a white powder, which is soluble in water. In this study ceftriaxone crystalline powder will be dissolved in 0.9% sodium chloride solution prior to intra-peritoneal instillation.~Antibiotic instillation will be introduced into the RLQ/pelvis after the appendectomy is completed and all intra-peritoneal fluid is aspirated. Ceftriaxone solution will be used depending on availability and pharmacy stock for use at Johns Hopkins All Children's Hospital. The ceftriaxone powder (2g) will be dissolved in 9ml of sterile normal saline, for a total instillation volume of 10ml. This fluid will then be instilled and left to dwell in the area of the peritoneal cavity where the appendix was removed.
Study: NCT06154447
Drug: VX-828
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for Oral Administration
Study: NCT06154447
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for Oral Administration
Study: NCT06154447
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Syrup for Oral Administration
Study: NCT06154447
Drug: Tezacaftor
Normalized name: Tezacaftor
DrugBank: Tezacaftor (DB11712)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets for Oral Administration
Study: NCT06154447
Drug: VX-118
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for Oral Administration
Study: NCT05788965
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: glucagon-like peptide 1 (GLP-1) receptor agonist
Study: NCT06545929
Drug: Sunobinop
Normalized name: Sunobinop
DrugBank: Sunobinop (DB18955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet taken orally at bedtime
Study: NCT04676360
Drug: Belantamab Mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin will be administered intravenously at calculated dose on day 1 of each 21-day cycle.
Study: NCT04647890
Drug: FT011
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Two x 100mg capsules once daily for 12 weeks
Study: NCT04647890
Drug: FT011
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Two x 200mg capsules once daily for 12 weeks
Study: NCT05337033
Drug: MPL-001
Normalized name: MPL
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD50 plus is a medical cannabis oil with flavouring agent produced under Good Manufacturing Practice by MediPharm Labs and purchased for this study. Each ml of oil contains 2 mg/ml of delta-9-THC and 50 mg/ml of CBD.~Participants will receive escalating doses from 0.2-0.4 mg/kg/day of CBD to 0.8-1 mg/kg of CBD per day for four months, with dose increases monthly in 0.2mg/kg increments. Participants will following a weekly weaning protocol.
Study: NCT05567094
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 0.2 mg/kg dexamethasone, administered as an intravenous bolus within 5 minutes after induction of anesthesia
Study: NCT06392321
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: comparison between bupivacaine, bupivacaine and dexmedetomidine..
Study: NCT06545929
Drug: Placebo to match sunobinop
DrugBank: Sunobinop (DB18955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet taken orally at bedtime
Study: NCT06016413
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients received nab-paclitaxel 260 mg/m2 intravenously on day 1 of each 3-week cycle for 3 cycles.
Study: NCT06016413
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
Study: NCT06016413
Drug: adelbelimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
Study: NCT04675528
Drug: DHP107(Oral paclitaxel)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: DHP107 200 mg/m\^2 orally twice daily on Day 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m\^2 orally once daily on Day 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)
Study: NCT06702943
Drug: Colistimethate sodium (CMS)
Normalized name: Colistimethate Sodium
DrugBank: Colistimethate (DB01111)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colistimethate sodium-based regimen (standard therapy for MDR infections) administered both IV and IVT for 14-21 days.
Study: NCT05287360
Drug: Rivoceranib
Normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.
Study: NCT06702670
Drug: Treatment with Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine 50mg IV will be administered within 1 hour of the cervical exam which diagnosed prolonged active phase of labor
Study: NCT04579367
Drug: Bempedoic acid and/or its fixed-dose combination with ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This is a non-interventional study. No study medication will be provided to the patients. Medication will be prescribed by the treating physician in line with the clinical practice.